What the results might mean for the future of other developers in the cannabinoid receptor 1 (CB1) weight-loss arena came into question after Novo Nordisk A/S unveiled phase IIa findings with ...
If confirmed, he would be the first person to serve in this position which was created in 2022. Novo Nordisk CEO Lars Jergensen testified on the company's pricing for its diabetes and weight loss ...